Treatment-related mortality. Treatment-related mortality was examined in a competing risk fashion, with relapse as the competing risk. The 1-year cumulative incidence of TRM in the Tac/Sir group was 13% compared with 30% in the Tac/Sir/Mtx group and 26% in the Tac/Mtx group (P < .001).